Unidade de Investigación en Cardioloxía Celular e Molecular
C.C.M.
![Foto de Unidade de Investigación en Cardioloxía Celular e Molecular](/img/grupo.png)
![Foto de St. Michael's Hospital](/img/noimage_org.png)
St. Michael's Hospital
Toronto, CanadáPublicacións en colaboración con investigadores/as de St. Michael's Hospital (8)
2023
-
Survival after Invasive or Conservative Management of Stable Coronary Disease
Circulation, Vol. 147, Núm. 1, pp. 8-19
2022
-
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
Nature Medicine, Vol. 28, Núm. 12, pp. 2512-2520
2021
-
Empagliflozin in heart failure with a preserved ejection fraction
New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461
-
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433
2020
-
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392
2019
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628
2018
-
Alirocumab and cardiovascular outcomes after acute coronary syndrome
New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107
2012
-
Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada
European Journal of Preventive Cardiology, Vol. 19, Núm. 2, pp. 221-230